Mannkind (MNKD) EBIT (2010 - 2026)
Mannkind (MNKD) reported EBIT of -$1.7 million for Q1 2026, down 107.48% year-over-year from $22.3 million in Q1 2025, and up 78.31% on a QoQ basis from -$7.7 million in Q4 2025.
Mannkind (MNKD) has 17 years of EBIT data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly EBIT fell 107.48% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (down 81.01% YoY) and the FY2025 annual result came in at $38.8 million, down 46.55% from the prior year.
- EBIT grew to -$1.7 million in Q1 2026 per MNKD's latest filing, from -$7.7 million in the prior quarter.
- Across five years, EBIT topped out at $26.5 million in Q4 2024 and bottomed at -$21.3 million in Q1 2022.
- The 5-year median for EBIT is $5.1 million (2023), against an average of $3.2 million.
- The widest annual swing landed in 2022, when EBIT slumped 243.34%; it then surged 865.14% in 2024.
- Tracing MNKD's EBIT over 5 years: stood at -$12.8 million in 2022, then jumped by 161.44% to $7.9 million in 2023, then soared by 237.17% to $26.5 million in 2024, then plunged by 129.01% to -$7.7 million in 2025, then jumped by 78.31% to -$1.7 million in 2026.
- Per Business Quant, the three latest MNKD EBIT figures stand at -$1.7 million (Q1 2026), -$7.7 million (Q4 2025), and $18.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | -1.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.67 Mn |
| Dec 31, 2025 | -7.69 Mn |
| Sep 30, 2025 | 18.90 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 22.29 Mn |
| Dec 31, 2024 | 26.50 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | 16.61 Mn |
| Mar 31, 2024 | 16.72 Mn |
| Dec 31, 2023 | 7.86 Mn |
| Sep 30, 2023 | 5.10 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Dec 31, 2022 | -12.79 Mn |
| Sep 30, 2022 | -9.61 Mn |
| Jun 30, 2022 | -20.45 Mn |
| Mar 31, 2022 | -21.26 Mn |
| Dec 31, 2021 | -23.97 Mn |
| Sep 30, 2021 | -6.59 Mn |
| Jun 30, 2021 | -10.27 Mn |
| Mar 31, 2021 | -6.19 Mn |
| Dec 31, 2020 | -23.75 Mn |
| Sep 30, 2020 | -9.13 Mn |
| Jun 30, 2020 | -7.92 Mn |
| Mar 31, 2020 | -7.12 Mn |
| Dec 31, 2019 | -11.35 Mn |
| Sep 30, 2019 | -8.78 Mn |
| Jun 30, 2019 | -10.95 Mn |
| Mar 31, 2019 | -13.51 Mn |
| Dec 31, 2018 | -7.73 Mn |
| Sep 30, 2018 | -21.54 Mn |
| Jun 30, 2018 | -20.54 Mn |
| Mar 31, 2018 | -26.79 Mn |
| Dec 31, 2017 | -28.84 Mn |
| Sep 30, 2017 | -28.18 Mn |
| Jun 30, 2017 | -31.57 Mn |
| Mar 31, 2017 | -19.60 Mn |
| Dec 31, 2016 | -11.83 Mn |
| Sep 30, 2016 | 118.23 Mn |
| Jun 30, 2016 | -19.12 Mn |
| Mar 31, 2016 | -20.01 Mn |
| Dec 31, 2015 | -272.86 Mn |
| Sep 30, 2015 | -26.00 Mn |
| Jun 30, 2015 | -24.05 Mn |
| Mar 31, 2015 | -21.74 Mn |
| Dec 31, 2014 | -30.10 Mn |
| Sep 30, 2014 | -38.27 Mn |
| Jun 30, 2014 | -69.85 Mn |
| Mar 31, 2014 | -41.41 Mn |
| Dec 31, 2013 | -46.62 Mn |
| Sep 30, 2013 | -44.76 Mn |
| Jun 30, 2013 | -41.59 Mn |
| Mar 31, 2013 | -36.44 Mn |
| Dec 31, 2012 | -33.49 Mn |
| Sep 30, 2012 | -35.49 Mn |
| Jun 30, 2012 | -44.05 Mn |
| Mar 31, 2012 | -33.93 Mn |
| Dec 31, 2011 | -30.58 Mn |
| Sep 30, 2011 | -32.77 Mn |
| Jun 30, 2011 | -39.19 Mn |
| Mar 31, 2011 | -38.00 Mn |
| Dec 31, 2010 | -32.09 Mn |
| Sep 30, 2010 | -42.54 Mn |
| Jun 30, 2010 | -37.26 Mn |